Tissue-Resident Memory T Cells Underlie Neoadjuvant Immunotherapy Response

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Neoadjuvant immunotherapy aims to enhance anti-tumor immunity before surgery.
• Understanding the characteristics of immune cells responding to therapy is critical for optimizing treatment efficacy.
• CD8+ T cells are key players in cell-mediated immunity against cancer.

Purpose of the Study:

• To investigate the gene expression profiles of CD8+ T cells that respond to neoadjuvant immunotherapy.
• To determine if these responsive CD8+ T cells exhibit specific immune memory phenotypes.

Main Methods:

• Analysis of tumor-infiltrating lymphocytes (TILs) from patients undergoing neoadjuvant immunotherapy.
• Transcriptomic analysis (e.g., RNA sequencing) to identify gene expression patterns.
• Bioinformatic analysis to characterize T cell populations and their functional states.

Main Results:

• CD8+ T cells demonstrating a response to neoadjuvant immunotherapy were identified.
• These responsive CD8+ T cells showed significant upregulation of gene programs associated with tissue-resident memory T cells (TRM).
• Upregulated genes included those involved in T cell retention, survival, and local effector functions within the tumor microenvironment.

Conclusions:

• Responsive CD8+ T cells in the context of neoadjuvant immunotherapy are characterized by a tissue-resident memory phenotype.
• This TRM signature suggests enhanced local immune surveillance and effector function within the tumor.
• These findings may inform the development of more effective immunotherapy strategies by targeting or enhancing TRM cell populations.